Considering offers from two MM investment banks: MTS and Leerink. Any insight into how they are doing (recent activity), quality of MD hires, relative strength in verticals (services, biopharma, etc.)?
Anything is appreciated.
| +235 | Who Killed Wall Street | 65 | 2d |
| +194 | Worlds Worst MDs Competition (2026 Edition) | 44 | 1h |
| +167 | As Lehman people reconvene at UBS, Barclays needs to hire (2023) | 23 | 6d |
| +130 | Only Indians cold emailing | 44 | 8h |
| +125 | Lindsay Clancy - Thoughts from A2 | 22 | 3d |
| +69 | UBS Healthcare | 34 | 19m |
| +50 | Shana tova - happy new year | 6 | 10h |
| +48 | NYC Wall Street Run Club | 13 | 7h |
| +45 | More diversity needed in the industry | 11 | 17h |
| +43 | EB (EVR/CVP/LAZ) vs MBB (Bain/BCG) | 22 | 48m |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
^following
Did a coffee chat with someone from MTS years ago, sounded like you can have some say in regards to the vertical you want to focus on (biopharma is historically their best vertical).
Know a few bankers there and one of their partners (ex-BB MD) supposedly was unanimously seen as their biggest rainmaker. Not sure about their recent hires.
I’d say MTS, know several people there and have only heard great things about culture/hours/comp.
Also talked to a VP who used to work for SVB Securities before it went under, he said it was a sweatshop. But that was several years ago and it might be better now after the Leerink re-rebrand idk
MTS for sure
You can literally check online - MTS mostly deals w $100mm or NFP deals (and some Japan stuff). Leerink does better
Leerink recently completely overhauled their M&A team. Their new co-president is one of the co-founders of PJT and they also hired a couple MDs from Guggenheim and Gordan Dyal. They just advised GSK on its acquisition of IDRx, and a few other M&A deals. I imagine they want to climb higher on the M&A LTs. Also they are at the top of the league tables in Biopharma ECM and churn out multiple FOs, PIPEs, ATMs, etc. per month. MTS is strictly M&A and they do a few $1B+ deals a year, I believe. MTS I have heard also has a fantastic culture/comp and Leerink’s has been iffy at times but believe its improving but who knows. If you’re joining Leerink, you may be doing a bit more “building the brand” type work for the M&A side rather than at MTS where they have been mandated a few times on large deals already. Both of them are great choices and good banks within Biopharma.
Voluptatem ad facilis pariatur. Placeat non ea alias voluptatum aut voluptas ut eligendi. Itaque voluptas laboriosam quia autem et dolorem. Non assumenda ipsa deserunt qui est porro.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...